Multi-omics molecular treatment targets for Prostate Cancer

Información del proyecto

PCaProTreat

Identificador del acuerdo de subvención: 800048

DOI 10.3030/800048

Proyecto cerrado

Fecha de la firma de la CE 15 Marzo 2018

Fecha de inicio 1 Abril 2018

Fecha de finalización 31 Marzo 2020

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total € 171 460,80

Aportación de la UE € 171 460,80

Coordinado por

MOSAIQUES DIAGNOSTICS GMBH
Germany

Objetivo

The PCaProTreat Project targets on improving the Prostate Cancer (PCa) management and focuses on the identification of novel therapeutic targets for patients with an advanced disease stage. It has been demonstrated that the current medical practice has led to frequent over-treatment of patients exhibiting slow growing PCa (unlikely to progress in the absence of treatment), while for metastatic castration resistant patients that immediate treatment is required, no effective strategies are available. Therefore, new therapeutic options are required for advanced PCa. To address this clinical demand, PCaProTreat is focused on the comprehensive characterisation of the molecular background of PCa progression, based on which molecularly-driven therapeutic targets can be defined. Towards that end, PCaProTreat includes: a) multi-layer analysis (different types of specimens: tissue, urine, seminal plasma) and multi-omics profiling (proteomics, peptidomics, transcriptomics), supplemented with literature-mined data, b) establishment of the PCa knowledge database, c) data integration into Systems Biology workflow to identify key-regulatory elements responsible for disease progression (best suited drug targets) and d) validation of the selected targets using immunohistochemistry. This multi-dimensional approach represents a substantial advancement over the standards currently applied in drug discovery process, allowing to overcome the challenges associated with tumour heterogeneity and thus reveal optimal drug targets. In parallel to the research activities, a multi-disciplinary and multi-sectorial training program will be implemented to increase the competitiveness of the ER within the research community, to become a recognised researcher. Activities will be carried out in the industrial sector, with Mosaiques Diagnostics a leader in clinical proteomics and Systems Medicine, being a Host institution.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véase: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• ciencias médicas y de la salud › medicina básica › farmacología y farmacia › descubrimiento de fármacos
• ciencias médicas y de la salud › medicina clínica › oncología › cáncer de próstata
• ciencias naturales › ciencias biológicas › bioquímica › biomoléculas › proteínas › proteómica
• ciencias naturales › informática y ciencias de la información › base de datos

Para utilizar esta función, debe iniciar sesión o registrarse

Programa(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Tema(s)

• MSCA-IF-2017 - Individual Fellowships

Convocatoria de propuestas

H2020-MSCA-IF-2017

Régimen de financiación

MSCA-IF-EF-SE - Society and Enterprise panel

Coordinador

MOSAIQUES DIAGNOSTICS GMBH

• Aportación neta de la UEn: € 171 460,80
• Dirección: ROTENBURGER STRASSE 20 ; 30659 Hannover ; Alemania
• Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí:
  Región
  Niedersachsen › Hannover › Region Hannover
• Región: Niedersachsen › Hannover › Region Hannover
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 171 460,80